Aravive (NASDAQ:ARAV) announced its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.44, Fidelity Earnings reports. The company had revenue of $1.70 million during the quarter.
NASDAQ ARAV opened at $5.81 on Friday. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $15.30. The firm has a market capitalization of $65.54 million, a PE ratio of -0.55 and a beta of 2.47. The company has a quick ratio of 7.78, a current ratio of 7.78 and a debt-to-equity ratio of 0.17.
An institutional investor recently bought a new position in Aravive stock. Geode Capital Management LLC purchased a new position in Aravive Inc (NASDAQ:ARAV) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 29,959 shares of the company’s stock, valued at approximately $105,000. Geode Capital Management LLC owned about 0.27% of Aravive as of its most recent SEC filing. Hedge funds and other institutional investors own 27.57% of the company’s stock.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Featured Article: What is a Fiduciary?
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.